BioCentury
ARTICLE | Clinical News

Genasense oblimersen sodium injection: Completed Phase III enrollment

April 13, 2009 7:00 AM UTC

Genta completed enrollment of 315 patients in the double-blind, placebo-controlled, international Phase III AGENDA trial evaluating 7 mg/kg/day of IV Genasense given for the first 5 days of a 21-day c...